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Objectives:  This  report  presents  the  French  Society  of  ORL  (SFORL)  guidelines  for  exploration
for remote  metastasis  and  synchronous  second  cancer  in  initial  staging  of  head  and  neck  squa-
mous cell  carcinoma.
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Materials  and  methods:  An  exhaustive  literature  review  was  analyzed  by  a  multidisciplinary
work-group.
Results: The  thorax  is  the  most  frequent  location  of  remote  metastases  and  synchronous  sec-
ond cancer  outside  of  the  upper  aerodigestive  tract.  Thoracic  CT  is  recommended  as  ﬁrst-line
examination  in  all  cases  (grade  B).  18-FDG  PET/CT  is  recommended  when  the  thoracic  CT
image is  doubtful  or  in  case  of  high  metastatic  risk  (grade  B),  for  the  detection  of  non-
pulmonary  remote  metastasis.  Esophageal  exploration  is  recommended  in  case  of  signiﬁcant
risk of  synchronous  esophageal  cancer  (hypopharyngeal  or  oropharyngeal  tumor,  chronic  alcohol
intoxication)  (grade  B).  The  reference  examination  is  ﬂexible  endoscopy  of  the  upper  digestive
tract (grade  B).
Conclusion:  The  present  grade  B  recommendations  rationalize  the  roles  of  the  various  ﬁrst-
line radiological  and  endoscopic  examinations  for  remote  metastasis  and  synchronous  second
cancer, so  as  to  limit  the  number  of  examinations  performed,  thereby  reducing  the  time  needed
for initial  staging.
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extension  (heavy  surgery,  potentialized  radiation  therapy).©  2012  Elsevier  Masson  SAS
Pre-treatment  assessment  of  squamous  cell  carcinoma  of
he  oral  cavity,  larynx  and  pharynx  (excluding  the  nasopha-
ynx)  is  controversial.  Part  1  of  the  present  guideline  dealt
ith  initial  local  and  cervical  lymph-node  assessment.  Part  2
eals  with  assessment  of  remote  extension  and  synchronous
econd  cancer  outside  of  the  upper  aerodigestive  tract.
The  ﬁrst  section  presents  the  main  anatomic  locations
f  remote  metastasis  and  means  of  detection.  Section  2
resents  the  two  most  frequent  synchronous  tumor  loca-
ions:  lung  and  esophagus.  Frequencies,  risk  factors  and
eans  of  detection  are  analyzed.
Guidelines  based  on  levels  of  evidence  are  presented  for
ach  entity;  when  the  level  of  evidence  is  insufﬁcient,  a
rofessional  consensus  is  put  forward.
emote extension assessment (exploration for
emote metastasis)
Exploration  for  remote  metastasis:  SFORL  guide-
lines:
•  systematic  thoracic  CT  (Grade  B);
•  18FDG-PET/CT  in  elevated  metastatic  risk  (stages  III
and  IV  with  multiple  or  low-lying  adenopathy)  or  in
case  of  inconclusive  thoracic  CT  image  (professional
consensus);
•  chest  X-ray  is  not  recommended  in  these  indications
(Grade  B);
•  systematic  liver  US  scan,  bone  scintigraphy  or  cere-
bral  CT  scan  are  not  recommended.  (professional
consensus).
There  have  been  no  studies  clearly  determining  the  rate
f  metastasis  at  the  time  of  discovery  of  the  primary  tumor,
ut  the  incidence  would  appear  to  be  fairly  low.  Remote
etastasis  generally  leads  to  palliative  treatment  adapted
o  a  poor  prognosis.  Thus,  discovery  of  remote  metastasis  at
he  time  of  diagnosis  impacts  management  of  the  primary
umor.  If  there  is  any  risk  of  metastasis,  exploration  should
e  implemented.
1
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Between  7%  and  10%  of  patients  show  metastatic  evolu-
ion  during  treatment  [1—4]. Data  from  these  studies  were
nalyzed  to  assess  relative  risk  according  to  metastatic  loca-
ion  and  to  determine  diagnostic  strategy.
The  main  risk  factors  for  remote  metastasis  are  well-
stablished  [1,2,4—10]:
 regional  lymph-node  extension,  regardless  of  T  stage,
with  risk  correlating  to  N  stage;
 tumor  volume,  with  metastasis  risk  correlating  to  T  stage;
 head  and  neck  location,  with  higher  risk  associated  with
hypopharyngeal  tumor.
The  most  frequent  remote  metastatic  location  is  the  pul-
onary  parenchyma  (45—55%),  followed  by  bone  (3—10%)
nd  liver  (<  5%)  [2,4,11]. In  almost  a  third  of  cases,  metas-
asis  involves  several  locations  at  once.
In  the  literature,  pulmonary  metastasis  and  a  possible
ynchronous  second  pulmonary  primary  are  often  explored
or  in  a  single  analysis.  These  two  different  pathologies
ay  present  in  the  same  form,  as  rounded  parenchymatous
odules.  The  existence  of  several  synchronous  pulmonary
odules  does  not  always  prove  metastasis:  several  primary
ulmonary  tumors  may  coexist,  sometimes  with  differing
istology  [12];  histology  fails  to  differentiate  between  the
wo  entities  in  the  case  of  squamous  cell  carcinoma  [13].
horacic  CT  has  consistently  proved  better  than  plain  chest
-ray  in  terms  of  sensitivity  and  speciﬁcity  in  detecting
uspect  pulmonary  nodules  [14—21].  Not  all  pulmonary  nod-
les  are  cancerous,  even  when  synchronous  with  head  and
eck  cancer.  Several  studies  have  shown  the  interest  of
8FDG-PET  coupled  to  CT  (18FDG-PET/CT)  in  differentiating
uspect  images  found  on  CT  alone  [22,23].
Extra-pulmonary  metastasis  is  not  systematically  associ-
ted  with  pulmonary  metastasis.  In  case  of  high  metastatic
isk  (stages  III  or  IV  with  multiple  or  low-lying  adenopathy),
8FDG-PET/CT  is  recommended  whatever  the  thoracic  CT
ndings,  to  avoid  subjecting  the  patient  to  potentially  tir-
ng,  toxic  or  mutilating  treatment  not  adapted  to  disease8FDG-PET/CT  has  the  advantage  of  providing  full-body
xploration  with  excellent  sensitivity.  In  a  meta-analysis
omprising  1276  patients,  mean  sensitivity  and  speciﬁcity
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of  18FDG-PET/CT  in  detecting  extra-cervical  locations  dur-
ing  initial  head  and  neck  cancer  staging  were  respectively
88%  and  93.3%  [24].  18FDG-PET/CT  is  further  recommended
by  the  National  Comprehensive  Cancer  Network  in  stages  III
or  IV  or  if  detection  of  remote  locations  will  impact  local
treatment  (NCCN  2011);  if  extra-pulmonary  metastasis  is
suspected  on  imaging,  targeted  exploration  should  be  under-
taken:  biological,  radiological  (plain  X-ray,  ultrasound,  MRI,
CT,  bone  scintigraphy),  histology.
Exploration for  secondary locations outside
the upper aerodigestive tract
‘‘Synchronous’’  refers  to  second  cancers  diagnosed  at
the  same  time  as  or  within  6  months  of  the  primary;
‘‘metachronous’’  refers  to  those  diagnosed  later  than
6  months.  Most  head  and  neck  squamous  cell  carcinomas
are  associated  with  chronic  nicotine  and/or  alcohol  intox-
ication,  and  such  patients  are  at  increased  risk  of  second
cancer  with  the  same  risk  factors.  By  order  of  frequency,
second  locations  are  upper  aerodigestive  tract,  lung  and
esophagus.
Incidence  of  metachronous  second  cancer  at  whatever
location  is  estimated  at  4%  to  7%  per  year  [25].  In  a  large-
scale  analysis  of  13  registries  totaling  99,257  patients,  the
main  risk  was  onset  in  another  head  and  neck  location,  with
cumulative  risk  of  36%  over  20  years,  the  second  being  the
development  of  a  primary  bronchial  cancer,  with  cumulative
risk  of  13%  over  20  years  [26].
Pre-treatment  assessment  concerns  diagnosis  of  syn-
chronous  cancer  to  the  extent  that  discovery  may  impact
management  of  the  ﬁrst.
Exploration  for  a  synchronous  second  pulmonary
location
Exploration  for  a  synchronous  second  pulmonary
location:  SFORL  guidelines:
•  systematic  thoracic  CT  (Grade  B);
•  18FDG-PET/CT  in  case  of  inconclusive  thoracic  CT
image  (Grade  B);
•  in  case  of  suspected  primary  bronchopulmonary  car-
cinoma  on  thoracic  CT,  a  pneumologist’s  opinion
should  be  sought.  Systematic  tracheobronchial  ﬂex-
ible  endoscopy  is  not  recommended  (professional
consensus).
Incidence  of  primary  bronchial  cancer  synchronous  with
head  and  neck  squamous  cell  carcinoma  is  estimated  at  0.3%
to  3%  [27—30].
Primary  bronchial  cancer  is  the  third  most  frequent  form
of  cancer,  after  colorectal  and  breast  cancer,  but  is  asso-
ciated  with  the  highest  mortality:  30,651  new  cases  and
26,624  deaths  in  2005  in  France  [31].  Risk  factors  are  well-
established:
f
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 active  smoking  is  the  main  risk  factor:  in  2000,  85%  of
primary  bronchial  cancers  implicated  smoking  [32];
 the  role  of  passive  smoking  has  been  known  since  the
1980s;  in  1998,  a  meta-analysis  found  26%  elevation  of
risk  of  bronchial  cancer  in  non-smokers  living  in  contact
with  smokers  [33];
 other  risk  factors  have  been  identiﬁed,  mainly  impli-
cated  in  occupational  cancer:  exposure  to  asbestos,  silica,
nickel,  hexavalent  chromium,  cadmium,  paint  or  radon
[34].
Some  patients  develop  primary  bronchial  cancer  with-
ut  displaying  any  identiﬁed  or  known  risk  factors.  Bronchial
ancer  in  non-smokers  is  the  seventh  most  frequent  cause  of
ancer  death  [35].  It  is  an  entity  in  itself,  characterized  by
emale  predominance,  adenocarcinoma  and  fairer  prognosis
36,37].
There  are  several  arguments  in  favor  of  systematic
creening  for  primary  bronchial  cancer  in  at-risk  popula-
ions:
 systematic  radiological  lung  cancer  screening  in  at-risk
populations  would  enable  early  stage  detection  [38,39];
 the  smaller  the  lesions  detected,  the  less  risk  of  mediasti-
nal  lymph-node  extension  [40];
 lung  cancer  tumor  size  is  an  independent  prognostic  factor
[41].
The  impact  of  systematic  screening  on  overall  survival
n  at-risk  populations,  however,  is  not  clear  [42]. Primary
ronchial  cancer  is  of  poorer  prognosis  when  synchronous
han  metachronous  [43].
As  in  exploration  for  pulmonary  metastasis,  the  ﬁrst-line
xamination  is  thoracic  CT,  being  more  effective  than  chest
-ray  in  detecting  parenchymatous  nodules  and  mediasti-
al  adenopathies  [14—21].  As  in  exploration  for  pulmonary
etastasis  once  again,  18FDG  PET/CT  should  be  performed
n  second  line  when  the  thoracic  CT  image  is  suspect  [22,23].
Tracheobronchial  ﬂexible  endoscopy  is  of  limited  inter-
st:  most  pulmonary  parenchymatous  nodules  diagnosed  on
horacic  CT  go  undetected  [44—46].  Its  usefulness  lies  in
etecting  early-stage  proximal  bronchial  tumor  invisible  on
-ray;  incidence,  however,  is  rare  [47].
xploration  for  a synchronous  second  esophageal
ocation
revalence  of  second  primary  esophageal  cancer  in  patients
reated  and  followed  for  head  and  neck  squamous  cell  car-
inoma  (oral  cavity,  oropharynx,  larynx,  hypopharynx)  is
stimated  at  0—21.9%  [47—52],  a  variability  explained  by
hat  of  the  populations  studied  in  terms  of  cancer  risk
actors,  head  and  neck  locations  and  esophageal  lesion
etection  techniques.
The  relative  risk  of  preneoplastic  lesion  of  esophageal
ancer  in  patients  treated  and  followed  for  head  and  neck
quamous  cell  carcinoma  varies  between  patients.  Two  risk
actors  have  been  identiﬁed:
 head  and  neck  squamous  cell  carcinoma  location,  with
elevated  risk  associated  with  hypopharynx  and  lowest  risk
110  
Exploration  for  a  synchronous  second  esophageal
location:  SFORL  guidelines:
•  systematic  esophageal  exploration  as  part  of  the  pre-
treatment  work-up  in  at-risk  patients  (hypopharynx
and  oropharynx  and/or  chronic  alcohol  intoxication)
(Grade  B);
•  recommended  reference  examination:  ﬂexible
esophageal  white-light  video  endoscopy,  with  tar-
geted  biopsies  of  all  suspect  mucosal  lesions  (Grade
B);
•  role  of  vital  staining,  such  as  Lugol:  diagnoses  more
early-stage  preneoplastic  and  neoplastic  lesions,
with  better  deﬁnition  of  local  extension  of  more
advanced  tumors;  optional  but  recommended.
Narrow-band  imaging  (NBI)  seems  promising,  but
remains  to  be  validated  (Grade  B);
•  alternative:  rigid  esophagoscopy  with  rigid  endo-
scope,  performed  during  panendoscopy.  This  exam-
ination,  however,  does  not  explore  the  lower
esophagus,  entails  a  risk  of  perforating  the  esoph-
agus  (especially  when  irradiated)  and  is  difﬁcult  to
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with  oral  cavity  and  larynx;  results  for  the  oropharynx  are
less  clear  [47—49,51]:  T  stage  in  head  and  neck  cancer  is
not  a  risk  factor  at  all,  even  in  the  hypopharynx;
 chronic  alcohol  intoxication,  which  is  a  risk  factor  inde-
pendent  of  smoking  [51],  and  increases  with  the  degree
of  intoxication.
There  are  two  main  arguments  in  favor  of  early  diagnosis
f  synchronous  esophageal  cancer:
 discovery  of  a  synchronous  esophageal  cancer  may  impact
respective  management  approaches  for  both  cancers.
Late  diagnosis  after  treatment  of  the  head  and  neck  can-
cer  could  hinder  that  of  the  esophageal  cancer  due  to
treatment  sequelae  or  restrictions  on  the  therapeutic
arsenal  (radiation  therapy  used  for  the  head  and  neck
cancer  might  exclude  reutilization  because  of  ﬁeld  over-
lap,  especially  in  the  cervical  esophagus).  Strategy  should
therefore  be  global,  so  that  treatment  of  one  cancer  is  not
to  the  cost  of  the  other;
 early  stage  preneoplastic  or  neoplastic  esophageal  lesions
may  beneﬁt  from  endoscopic  surgery,  whereas  more
advanced  forms  will  typically  be  managed  by  chemo-
radio-therapy.  Endoscopy  has  the  advantage  of  lighter
treatment  of  superﬁcial  early-stage  lesions,  without  com-
promising  the  treatment  of  the  head  and  neck  cancer.
Lugol  vital  staining  during  ﬂexible  esophageal  endoscopy
is  very  useful  in  detecting  early  stage  esophageal  lesions
especially  amenable  to  endoscopic  management  [50].
The  impact  of  screening  on  survival  remains  in  suspense:
o  reports  have  so  far  proved  any  positive  survival  impact
f  early  diagnosis  of  esophageal  lesions.
Incipient  neoplastic  esophageal  lesions  are  often  asymp-
omatic  and  go  undetected  on  CT  work-up  and  also  onE.  de  Monès  et  al.
8FDG  PET-CT  [30,53], requiring  meticulous  mucosal  explo-
ation.  Lacking  sensitivity,  imaging  is  not  recommended  as  a
eans  of  exploring  for  an  asymptomatic  synchronous  second
sophageal  location.
The  reference  screening  examination  is  ﬂexible  white-
ight  endoscopy,  also  known  as  esophageal  video-endoscopy
French  Society  of  Digestive  Endoscopy  (SFED)  guideline,  and
rofessional  consensus).  It  may  be  performed  under  local
nesthesia,  with  or  without  premedication,  or  under  gen-
ral  anesthesia.  It  provides  a  macroscopic  aspect  of  the
sophageal  mucosa,  enabling  targeted  biopsy  of  suspect
reas  (SFED  guidelines  for  digestive  biopsy  indications,  and
rofessional  consensus).
Lugol  staining  signiﬁcantly  enhances  the  sensitivity
f  ﬂexible  endoscopic  detection  of  preneoplastic  lesions
mucosal  dysplasia),  and  provides  a  more  precise  account
f  the  peripheral  superﬁcial  extension  of  macroscopic
esions  [48,51,54—56].  Lugol  vaporization  during  ﬂexi-
le  esophageal  endoscopy  may  induce  usually  moderate
nd  transient  side-effects:  bradycardia,  cough,  agitation,
sophageal  spasm  or  burning  sensation  [49].  The  presence
f  large  or  numerous  areas  of  Lugol  non-uptake  represents
 risk  factor  for  metachronous  esophageal  cancer  [57,58].
ugol  vaporization  identiﬁes  a  patient  subgroup  requiring
ubsequent  ﬂexible  esophageal  endoscopic  monitoring.
Rigid  esophagoscopy  is  in  our  opinion  a  second  choice,
eing  less  sensitive  and  with  higher  morbidity  [59].  The  risk
f  iatrogenic  esophageal  perforation  is  higher  in  case  of  pre-
ious  cervicomediastinal  radiation  therapy  [60].
onclusion
he  present  grade  B  guidelines  rationalize  the  respective
oles  of  the  various  ﬁrst-line  radiological  and  endoscopic
xplorations  for  remote  metastasis  and  synchronous  sec-
nd  cancer.  Thoracic  CT  is  reinforced  by  18FDG-PET/CT  in
atients  at  high  risk  of  remote  metastasis.  Flexible  tracheo-
ronchial  endoscopy  is  no  longer  recommended  as  a  ﬁrst
ine  examination.  Endoscopic  exploration  of  the  esophagus
s  recommended  in  certain  at-risk  patients.  This  rational-
zation  should  limit  the  number  of  examinations  and  thus
educe  the  time  needed  for  initial  staging.
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